<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340091</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1061</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091061</ELocationID><Abstract><AbstractText><b>Objective:</b> SARS-CoV-2 remains the third most common cause of death in North America. We studied the effects of methotrexate and tumor necrosis factor inhibitor (TNFi) on neutralization responses after COVID-19 vaccination in immune-mediated inflammatory disease (IMID). <b>Methods:</b> Prospective data and sera of adults with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA), and systemic lupus (SLE) were collected at six academic centers in Alberta, Manitoba, Ontario, and Quebec between 2022 and 2023. Sera from two time points were evaluated for each subject. Neutralization studies were divided between five laboratories, and each lab's results were analyzed separately using multivariate generalized logit models (ordinal outcomes: absent, low, medium, and high neutralization). Odds ratios (ORs) for the effects of methotrexate and TNFi were adjusted for demographics, IMID, other biologics and immunosuppressives, prednisone, COVID-19 vaccinations (number/type), and infections in the 6 months prior to sampling. The adjusted ORs for methotrexate and TNFi were then pooled in random-effects meta-analyses (separately for the ancestral strains and the Omicron BA1 and BA5 strains). <b>Results:</b> Of 479 individuals (958 samples), 292 (61%) were IBD, 141 (29.4%) were RA, and the remainder were PsA, SpA, and SLE. The mean age was 57 (62.2% female). For both the individual labs and the meta-analyses, the adjusted ORs suggested independent negative effects of TNFi and methotrexate on neutralization. The meta-analysis adjusted ORs for TNFi were 0.56 (95% confidence interval (CI) 0.39, 0.81) for the ancestral strain and 0.56 (95% CI 0.39, 0.81) for BA5. The meta-analysis adjusted OR for methotrexate was 0.39 (95% CI 0.19, 0.76) for BA1. <b>Conclusions:</b> SARS-CoV-2 neutralization in vaccinated IMID was diminished independently by TNFi and methotrexate. As SARS-CoV-2 circulation continues, ongoing vigilance regarding optimized vaccination is required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hitchon</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-5547-3268</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowdish</LastName><ForeName>Dawn M E</ForeName><Initials>DME</Initials><Identifier Source="ORCID">0000-0001-6823-2957</Identifier><AffiliationInfo><Affiliation>McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4L8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boire</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2481-5821</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-7278-2596</Identifier><AffiliationInfo><Affiliation>Centre de Recherche ARThrite-UL, Division of Rheumatology, Department of Medicine, CHU de Québec, Université Laval, Québec City, QC G1V 4G2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec, Université Laval, Québec City, QC G1V 4G2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flamand</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec, Université Laval, Québec City, QC G1V 4G2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dayam</LastName><ForeName>Roya M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gingras</LastName><ForeName>Anne-Claude</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1X5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Card</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3T 2N2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colmegna</LastName><ForeName>Inés</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larché</LastName><ForeName>Maggie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Gilaad G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-2719-0556</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukusa</LastName><ForeName>Luck</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0003-6435-8140</Identifier><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jennifer L F</ForeName><Initials>JLF</Initials><Identifier Source="ORCID">0000-0002-5501-0017</Identifier><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernatsky</LastName><ForeName>Sasha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9515-2802</Identifier><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The Succeed Investigative Team</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2122-HQ-000070</GrantID><Agency>Public Health Agency of Canada</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">TNF-blocking antibody</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">immune-mediated inflammatory disease</Keyword><Keyword MajorTopicYN="N">methotrexate</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor inhibitors</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Dr. Boire has received honoraria (none relevant to this work) for speaking or consultancy from Abbvie, BMS, Lilly, Novartis, Pfizer, Samsung BioEpis, Viatris; multi-centric research grants (none relevant to this work) from Janssen and Pfizer; unrestricted grant support (none relevant to this work) for local initiatives from BMS, Lilly and Pfizer. Dr. Bowdish is the Canada Research Chair in Aging &amp; Immunity. Dr. Chandran has received research grants (none relevant to this work) from AbbVie, Amgen, and Eli Lilly and has received honoraria (none relevant to this work) for advisory board member roles from AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. His spouse is an employee of AstraZeneca. Dr. Gingras has received research funds from a research contract with Providence Therapeutics Holdings, Inc., for other projects, participated in the COVID-19 Immunity Task Force (CITF) Immune Science and Testing working party, chaired the CIHR Institute of Genetics Advisory Board, and chairs the SAB of the National Research Council of Canada Human Health Therapeutics Board. Dr. Gingras is the Canada Research Chair, Tier 1, in Functional Proteomics. Dr. Hitchon participated in advisory boards for Astra-Zeneca (not related to this work) and has received research grants (unrelated to this work) for multi-centric research and from Pfizer (unrelated to this work).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340091</ArticleId><ArticleId IdType="pmc">PMC11436066</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091061</ArticleId><ArticleId IdType="pii">vaccines12091061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Statistic Canada  Leading Causes of Death, Total Population, by Age Group.  [(accessed on 29 July 2024)].  Available online:  https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401.</Citation></Reference><Reference><Citation>Dayam R.M., Law J.C., Goetgebuer R.L., Chao G.Y., Abe K.T., Sutton M., Finkelstein N., Stempak J.M., Pereira D., Croitoru D., et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases. JCI Insight. 2022;7:e159721. doi: 10.1172/jci.insight.159721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.159721</ArticleId><ArticleId IdType="pmc">PMC9220925</ArticleId><ArticleId IdType="pubmed">35471956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A., Stacey H.D., D’Agostino M.R., Tugg Y., Marzok A., Miller M.S. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 2023;23:381–396. doi: 10.1038/s41577-022-00813-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00813-1</ArticleId><ArticleId IdType="pmc">PMC9761659</ArticleId><ArticleId IdType="pubmed">36536068</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmegna I., Valerio V., Amiable N., Useche M., Rampakakis E., Flamand L., Rollet-Labelle E., Bessette L., Fitzcharles M.A., Hazel E., et al. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): Safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series. RMD Open. 2023;9:e003400. doi: 10.1136/rmdopen-2023-003400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2023-003400</ArticleId><ArticleId IdType="pmc">PMC10689388</ArticleId><ArticleId IdType="pubmed">38030231</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers B.L., Gelbart T., Tan G.S. A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay. STAR Protoc. 2022;3:01835. doi: 10.1016/j.xpro.2022.101835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2022.101835</ArticleId><ArticleId IdType="pmc">PMC9579189</ArticleId><ArticleId IdType="pubmed">36595901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchon C.A., Mesa C., Bernstein C.N., Marrie R.A., Card C., O’Brien S.F., Kim J. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: A single-centre prospective cohort study. BMJ Open. 2023;13:e071397. doi: 10.1136/bmjopen-2022-071397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-071397</ArticleId><ArticleId IdType="pmc">PMC10230332</ArticleId><ArticleId IdType="pubmed">37253487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.Q., Li H.J., Chen L., Lin S.P. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases. Sci. Rep. 2022;12:17955. doi: 10.1038/s41598-022-22839-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22839-0</ArticleId><ArticleId IdType="pmc">PMC9606114</ArticleId><ArticleId IdType="pubmed">36289319</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Núñez J.J., Muñoz-Valle J.F., Torres-Hernández P.C., Hernández-Bello J. Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines. 2021;9:1376. doi: 10.3390/vaccines9121376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121376</ArticleId><ArticleId IdType="pmc">PMC8706198</ArticleId><ArticleId IdType="pubmed">34960121</ArticleId></ArticleIdList></Reference><Reference><Citation>Imran M., Ali S., Ibrahim A.A., Amjad A., Tanveer A., Khalil S., Ali M., Abuelazm M. Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: A systematic review and meta-analysis. Clin. Rheumatol. 2024;43:2203–2214. doi: 10.1007/s10067-024-07013-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-024-07013-3</ArticleId><ArticleId IdType="pubmed">38802670</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman-Klapper H., Zittan E., Shitrit A.B.G., Rabinowitz K.M., Goren I., Avni-Biron I., Ollech J.E., Lichtenstein L., Banai-Eran H., Yanai H., et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with Anti-TNFα. Gastroenterology. 2022;162:454–467. doi: 10.1053/j.gastro.2021.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.029</ArticleId><ArticleId IdType="pmc">PMC8552587</ArticleId><ArticleId IdType="pubmed">34717923</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad C.G., Silva M.S., Sampaio-Barros P.D., Moraes J.C., Schainberg C.G., Gonçalves C.R., Shimabuco A.Y., Aikawa N.E., Yuki E.F., Pasoto S.G., et al. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis. Jt. Bone Spine. 2023;90:105464. doi: 10.1016/j.jbspin.2022.105464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2022.105464</ArticleId><ArticleId IdType="pmc">PMC9487175</ArticleId><ArticleId IdType="pubmed">36150668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Kennedy N.A., Saifuddin A., Sandoval D.M., Reynolds C.J., Seoane R.C., Kottoor S.H., Pieper F.P., Lin K.M., Butler D.K., et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat. Commun. 2022;13:1379. doi: 10.1038/s41467-022-28517-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28517-z</ArticleId><ArticleId IdType="pmc">PMC8927425</ArticleId><ArticleId IdType="pubmed">35296643</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner-Spitzer E., Wagner A., Gudipati V., Schoetta A.M., Orola-Taus M., Kundi M., Kunert R., Mayrhofer P., Huppa J.B., Stockinger H., et al. Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation. EBioMedicine. 2023;96:104788. doi: 10.1016/j.ebiom.2023.104788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104788</ArticleId><ArticleId IdType="pmc">PMC10485594</ArticleId><ArticleId IdType="pubmed">37672867</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R., Levy M.E., Gaglani M., Irving S.A., Stockwell M., Dascomb K., DeSilva M.B., Reese S.E., Liao I.C., Ong T.C., et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated—VISION Network, 10 States, December 2021–June 2022. MMWR Morb. Mortal Wkly. Rep. 2022;71:931–939. doi: 10.15585/mmwr.mm7129e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7129e1</ArticleId><ArticleId IdType="pmc">PMC9310634</ArticleId><ArticleId IdType="pubmed">35862287</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenat J.M., Noorishad P.G., Moshirian Farahi S.M.M., Darius W.P., Mesbahi El Aouame A., Onesi O., Broussard C., Furyk S.E., Yaya S., Caulley L., et al. Prevalence and factors related to COVID-19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta-analysis. J. Med. Virol. 2023;95:e28156. doi: 10.1002/jmv.28156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28156</ArticleId><ArticleId IdType="pmc">PMC9538578</ArticleId><ArticleId IdType="pubmed">36114154</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R., Dubois M., Ugarte-Gil M.F., Chaudier A., Kawka L., Bergier H., Costecalde C., Pijnenburg L., Fort J., Chatelus E., et al. Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. Rheumatology. 2021;60:SI68–SI76. doi: 10.1093/rheumatology/keab432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab432</ArticleId><ArticleId IdType="pmc">PMC8194533</ArticleId><ArticleId IdType="pubmed">33983432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>